shandong xinhua pharmaceutical (000756.SZ): Xinda Pharmaceuticals' Cefuroxime Axetil dispersible tablets passed the generic drug consistency evaluation.

On November 4th, Geruihui announced that Shandong Xinhua Pharmaceutical (000756.SZ) recently, Shandong Xinhua Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shandong Zibo Xinda Pharmaceutical Co., Ltd. (referred to as 'Xinda Pharmaceutical'), received the National Medical Products Administration's approval and issuance of the cephalosporin cefuroxime axetil dispersible tablets (referred to as 'this product') Supplementary Application Approval Notice for pharmaceuticals, approving this product to pass the generic drug quality and efficacy consistency evaluation. Cefuroxime axetil belongs to the second generation cephalosporin antibiotic, is the oral prodrug of the bactericidal cephalosporin antibiotic cefuroxime, is tolerant to most β-lactamases, and can be widely effective against gram-positive.

Gelonghui FinanceNov 4 03:54 ET

shandong xinhua pharmaceutical (00719.HK): Wholly-owned subsidiary's pharmaceutical products passed generic drug consistency evaluation.

Gelonghui November 4th | shandong xinhua pharmaceutical (00719.HK) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceuticals Co., Ltd. ("Xinda Pharmaceuticals"), recently received the National Medical Products Administration's approved and issued Ceftibuten Dispersible Tablets (referred to as "this product") "Drug Supplementary Application Approval Notice", approving this product through generic drug quality and efficacy consistency evaluation.

Gelonghui FinanceNov 4 03:42 ET

Express News | Shandong Xinhua Pharmaceutical - Drugs of Unit Passing Generics Consistency Evaluation

ReutersNov 4 03:41 ET

shandong xinhua pharmaceutical (00719.HK): Pentazonin has obtained the approval notice for the marketing application of chemical raw materials.

Gelonghui, November 4th - Shandong Xinhua Pharmaceutical (00719.HK) announced that the company recently received the approval notification for the market application of the chemical raw material Peratazosin issued by the National Medical Products Administration. After review, the product meets the relevant requirements for drug registration and has been approved for registration. The company is the third domestic enterprise to pass the approval of this active pharmaceutical ingredient.

Gelonghui FinanceNov 4 03:40 ET

Express News | Shandong Xinhua Pharmaceutical - Pentazocine Obtained Notification of Approval of Marketing Application for Chemical Substance Drugs

ReutersNov 4 03:40 ET

Hong Kong stock concept tracking | The end of medical insurance negotiations is very encouraging for innovative drugs to be included in medical insurance at reasonable prices (with concept stocks)

The on-site negotiation and bidding stages for the adjustment of the national medical insurance pharmaceutical catalog in 2024 officially ended recently.

Zhitong FinanceNov 3 20:45 ET